PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展

doi:10.11904/j.issn.1002-3070.2021.02.016

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (2): 184-187.doi: 10.11904/j.issn.1002-3070.2021.02.016

PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展

胡洋综述, 张清媛审校

哈尔滨医科大学附属肿瘤医院(哈尔滨 150081)

收稿日期:2020-06-01 修回日期:2020-08-06 出版日期:2021-04-28 发布日期:2021-04-27
通讯作者: 张清媛,E-mail:zqy123475@163.com
作者简介:胡洋,女,(1994-),硕士研究生,从事乳腺癌临床的研究。

Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer

HU Yang, ZHANG Qingyuan

Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2020-06-01 Revised:2020-08-06 Online:2021-04-28 Published:2021-04-27

摘要/Abstract

摘要： 近些年PARP抑制剂成为治疗乳腺癌临床研究新热点,大量研究证实其在BRCA1/2突变转移性乳腺癌患者中获益。本文就PARP抑制剂的作用机制和几种PARP抑制剂治疗BRCA1/2突变转移性乳腺癌患者的研究进展进行综述。

关键词: PARP抑制剂, BRCA1/2突变, 乳腺癌, 治疗进展

Abstract: In recent years,PARP inhibitors have become a new hot spot in clinical research on the treatment of breast cancer.A large number of studies have confirmed that they are beneficial in patients with BRCA1/2 mutant metastatic breast cancer.This article reviews the mechanism of PARP inhibitors and the research progress of several PARP inhibitors in the treatment of patients with BRCA1/2 mutated metastatic breast cancer.

Key words: PARP inhibitors;BRCA1/2 mutation;Breast cancer;Treatment progress

中图分类号:

R737.9

胡洋, 张清媛. PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 184-187.

HU Yang, ZHANG Qingyuan. Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer[J]. Journal of Practical Oncology, 2021, 35(2): 184-187.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.02.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I2/184

参考文献

1 Sulaiman A,Wang L.Bridging the divide:preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors[J].Oncotarget,2017,8(68):113269-113281.
2 Lewin R,Sulkes A,Shochat T,et al.Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations[J].Breast Cancer Res Treat,2016,157(3):511-516.
3 Akihiro O,Shinichi Y.Current status of poly(ADP-ribose)polymerase inhibitors and future directions[J].Onco Targets Ther,2017,10:5195-5208.
4 D'Andrea AD.Mechanisms of PARP inhibitor sensitivity and resistance[J].DNA Repair,2018,71:172-176.
5 Brown JS,Ocarrigan B,Jackson SP,et al.Targeting DNA repair in cancer:beyond PARP inhibitors[J].Cancer Discov,2017,7(1):20-37.
6 Evers B,Helleday T,Jonkers J.Targeting homologous recombination repair defects in cancer[J].Trends Pharmacol Sci,2010,31(8):372-380.
7 朱志超,白煜,卢绪章,等.PARP抑制剂olaparib对急性髓系白血病细胞HL-60抑制作用研究[J].实用肿瘤学杂,2019,33(6):481-485.
8 Eustermann S,Wu WF,Langelier MF,et al.Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1[J].Mol Cell,2015,60(5):742-754.
9 Vos MD,Schreiber V,Dantzer F.The diverse roles and clinical relevance of PARPs in DNA damage repair:Current state of the art[J].Biochem Pharmacol,2012,84(2):137-146.
10 Keung MYT,Wu Y,Vadgama JV.PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers[J].J Clin Med,2019,8(4):435.
11 Ashworth A,Lord CJ.Synthetic lethal therapies for cancer:what's next after PARP inhibitors?[J].Nat Rev Clin Oncol,2018,15(9):564-576.
12 Lord CJ,Ashworth A.PARP inhibitors:synthetic lethality in the clinic[J].Science,2017,355(6330):1152-1158.
13 Caulfield SE,Davis CC,Byers KF.Olaparib:a novel therapy for metastatic breast cancer in patients with a BRCA1/2 mutation[J].J Adv Pract Oncol,2019,10(2):167-174.
14 Gelmon K,Fasching P,Couch F,et al.Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer:Phase IIIb LUCY interim analysis[J].J Clin Oncol,2020,38:1087.
15 Shen Y,Rehman FL,Feng Y,et al.BMN 673,a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency[J].Clin Cancer Res,2013,19(18):5003-5015.
16 Turner NC,Telli ML,Rugo HS,et al.A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations(ABRAZO)[J].Clin Cancer Res,2019,25(9):2717-2724.
17 Ettl J,Quek RGW,Lee KH,et al.Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation:patient-reported outcomes from the EMBRACA phase III trial[J].Ann Oncol,2018,29(9):1939-1947.
18 Hoy SM.Talazoparib:first global approval[J].Drugs,2018,78(18):1939-1946.
19 Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer[J].N Engl J Med,2016,375(22):2154-2164.
20 USA National Library of Medicine.A feasibility study of niraparib for advanced,BRCA1-like,HER2-negative breast cancer patients[https://clinicaltrials.gov/ct2/show/NCT02826512].2016.
21 McCann KE,Hurvitz SA.Advances in the use of PARP inhibitor therapy for breast cancer[J].Drugs Context,2018,7:212540.
22 Han HS,Diéras V,Robson M,et al.Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer:randomized phase II study[J].Ann Oncol,2018,29(1):154-161.
23 Diéras V,Han HS,Kanfman B,et al.LBA9 Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer[J].Ann Oncol,2019,30:857-858.
24 Patsouris A,Vicier C,Campion L,et al.An open-label,phase II study of rucaparib,a PARP inhibitor,in HER2-metastatic breast cancer patients with high genomic loss of heterozygosity[J].J Clin Oncol,2017,35:1117.
25 Faraoni I,Graziani G.Role of BRCA mutations in cancer treatment with poly(ADP-ribose)polymerase(PARP)inhibitors[J].Cancers,2018,10(12):487.
26 Drew Y,Ledermann J,Hall G,et al.Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose)polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer[J].Br J Cancer,2016,114(7):723-730.
27 Wilson RH,Evans TJ,Middleton MR,et al.A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours[J].Br J Cancer,2017,116(7):884-892.
28 Keung MYT,Wu Y,Vadgama JV.PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers[J].J Clin Med,2019,8(4):435.

[1]	杨敏, 张娇燕, 段丹, 徐兵河. 乳腺癌照顾者研究的文献计量学及可视化分析[J]. 实用肿瘤学杂志, 2021, 35(2): 110-116.
[2]	王健宇, 张显玉, 庞达. Luminal A型乳腺癌新辅助化疗疗效的影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(2): 131-136.
[3]	朱云芳,文洪梅,秦明芳,石青萍,成会荣,高娇,陈杨. 2011—2016年云南省肿瘤登记地区女性乳腺癌发病和死亡情况分析[J]. 实用肿瘤学杂志, 2021, 35(1): 18-22.
[4]	牛明, 于歌. 促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J]. 实用肿瘤学杂志, 2020, 34(6): 518-523.
[5]	刘红, 鲁海玲, 蔡莉. 影像学预测乳腺癌患者预后及新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 535-539.
[6]	袁瑶, 周显礼. 乳腺癌超声特征与腋窝淋巴结转移相关性的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 576-580.
[7]	左婷婷, 吴颖, 董首兰, 曲宁, 高岿然, 李梦丹, 刘运泳. 辽宁省沈阳市城市地区2016-2018年度乳腺癌筛查结果分析[J]. 实用肿瘤学杂志, 2020, 34(5): 387-390.
[8]	赵仁成, 林子棠, 余卫军, 雷林, 刘峥, 徐英, 郭艳芳, 彭绩. 2017—2019年深圳市宝安区40~74岁常住居民五癌风险流行状况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 315-320.
[9]	仝潇, 邢佳妮, 王丽虹. 长链非编码RNA HCP5通过调控凋亡通路促进三阴性乳腺癌的研究[J]. 实用肿瘤学杂志, 2020, 34(4): 321-327.
[10]	刘思奇, 边娜娜, 苏亚娟. 超声BI-RADS联合血CA15-3和CEA在乳腺肿物诊断中的价值研究[J]. 实用肿瘤学杂志, 2020, 34(4): 347-351.
[11]	张锐, 李志高. 粘液性乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 377-381.
[12]	陈都, 钱诚. 乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 382-386.
[13]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.
[14]	李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.
[15]	赵云霞, 牛波. LncRNA NBAT1通过调控miR-3664-5p/Caspase 9分子轴对人乳腺癌细胞增殖的影响[J]. 实用肿瘤学杂志, 2020, 34(1): 24-29.

PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展

Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价